Steatohepatitis/Metabolic Liver Disease News

Among patients with nonalcoholic steatohepatitis in the United States, 20% progressed to cirrhosis within 4 years, with female sex and nonsmoking status linked to lower risk for progression, according to data from the TARGET-NASH trial.

EASL Congress 2023 has ended but, as the society’s official media partner, Healio was at the forefront covering the latest in liver disease. Wondering what you may have missed? Healio recaps the biggest news disrupting the specialty.

Modifying the timing of daily energy intake may improve metabolic health and restore natural circadian rhythms among patients with nonalcoholic fatty liver disease, according to a review published in Gut.

Endoscopic sleeve gastroplasty was more effective for weight loss than lifestyle modification alone in patients with nonalcoholic steatohepatitis and obesity, according to a speaker at EASL Congress.

SAN DIEGO — Diabetes and nonalcoholic fatty liver disease are “common bedfellows” due to processes brought on by insulin resistance, but a reduction in dietary sugars combined with exercise can reverse the damage, according to a speaker.

Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress.

  The FDA issued a complete response letter to Intercept indicating it cannot approve the company’s new drug application for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis.

Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results.

Patients with nonalcoholic fatty liver disease had a significantly greater risk for severe infection requiring hospitalization vs. the general population, with an absolute risk difference of more than 17%at 20 years after diagnosis.

In the race for a first-to-market therapy for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, there have been multiple hopeful contenders; however, none have yet crossed the FDA finish line.